Search Thermo Fisher Scientific
We offer multiple options for conjugating peptide antigens or haptens to immunogenic carrier proteins using strategies that optimize antigen presentation and antibody titer for custom antibody production services.
Our Targeted Antigen Display (TAD) Technology combines intelligent consideration of designed peptide structures, epitopes, and antigenicities with carefully selected combinations of conjugation methods to optimize antibody production with respect to intended assay applications. TAD Technology yields peptides that are conjugated in multiple, alternative conformations that mimic the presentation of epitopes in the native protein of interest based upon application. This process not only produces superior immunogens (i.e., higher antibody titer), but also results in antibodies that exhibit the best possible performance in different assay systems.
This is extremely important for generating antibodies that are assay-specific or can recognize changes in epitope conformation from one assay type to another. Although most of the individual carrier proteins and crosslinking strategies we offer represent well-established methods, TAD Technology provides unrivaled intelligence to the process of deciding among these individual options.
Researchers may select from the following list of common carrier proteins or submit to have another protein used.
We do not recommend amidation or acetylation of terminal residues unless the peptide is being used for kinematic studies or a previous method is being imitated. The chemistries used solely or in combination to present optimal, assay-specific epitopes for TAD are as follows:
For Research Use Only. Not for use in diagnostic procedures.